Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
- 1 November 2022
- journal article
- review article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (2) , 279-284
Abstract
Objective: Axial involvement in patients with psoriatic arthritis (PsA) is a common subset of this condition, but a unanimous definition has yet to be established. It has been defined by using different criteria, ranging from the presence of at least unilateral grade 2 sacroiliitis to those used for ankylosing spondylitis (AS), or simply the presence of inflammatory low back pain (IBP). Our aim was to identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA.Methods: This systematic review is an update of the axial PsA (axPsA) domain of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).Results: The systematic review of the literature showed that new biologic and targeted synthetic disease-modifying antirheumatic drug classes, namely interleukin (IL)-17A and Janus kinase inhibitors, could be considered for the treatment of axPsA. This would be in addition to previously recommended treatments such as nonsteroidal antiinflammatory drugs, physiotherapy, simple analgesia, and tumor necrosis factor inhibitors. Conflicting evidence still remains regarding the use of IL-12/23 and IL-23 inhibitors.Conclusion: Further studies are needed for a better understanding of the treatment of axPsA, as well as validated outcome measures.Keywords
This publication has 47 references indexed in Scilit:
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2013
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Annals of the Rheumatic Diseases, 2013
- Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?Clinical Rheumatology, 2012
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?Annals of the Rheumatic Diseases, 2010
- Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritisArthritis Care & Research, 2009
- Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 yearsArthritis Research & Therapy, 2009
- Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic ArthritisThe Journal of Rheumatology, 2009
- Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?Arthritis Care & Research, 2004
- The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity IndexArthritis Care & Research, 2004